Follow
Matthias Orth
Matthias Orth
Marienhospital Stuttgart
Verified email at vinzenz.de - Homepage
Title
Cited by
Cited by
Year
Expression of human apolipoprotein E3 or E4 in the brains ofApoE−/− mice: Isoform-specific effects on neurodegeneration
M Buttini, M Orth, S Bellosta, H Akeefe, RE Pitas, T Wyss-Coray, L Mucke, ...
Journal of Neuroscience 19 (12), 4867-4880, 1999
4531999
Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: Increased susceptibility of females
J Raber, D Wong, M Buttini, M Orth, S Bellosta, RE Pitas, RW Mahley, ...
Proceedings of the National Academy of Sciences 95 (18), 10914-10919, 1998
4331998
Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth
S Bellosta, BP Nathan, M Orth, LM Dong, RW Mahley, RE Pitas
Journal of Biological Chemistry 270 (45), 27063-27071, 1995
3751995
Cholesterol: its regulation and role in central nervous system disorders
M Orth, S Bellosta
Cholesterol 2012, 2012
3472012
Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n− 3 fatty acids
S Westphal, M Orth, A Ambrosch, K Osmundsen, C Luley
The American journal of clinical nutrition 71 (4), 914-920, 2000
2432000
Gangliosides in normal human serum: concentration, pattern and transport by lipoproteins
HJ SENN, M Orth, E Fitzke, H Wieland, W Gerok
European Journal of Biochemistry 181 (3), 657-662, 1989
1891989
The use of error and uncertainty methods in the medical laboratory
WP Oosterhuis, H Bayat, D Armbruster, A Coskun, KP Freeman, A Kallner, ...
Clinical Chemistry and Laboratory Medicine (CCLM) 56 (2), 209-219, 2018
1002018
Opinion: redefining the role of the physician in laboratory medicine in the context of emerging technologies, personalised medicine and patient autonomy (‘4P medicine’)
M Orth, M Averina, S Chatzipanagiotou, G Faure, A Haushofer, V Kusec, ...
Journal of clinical pathology 72 (3), 191-197, 2019
682019
Effects of a Frequent Apolipoprotein E Isoform, ApoE4Freiburg (Leu28→Pro), on Lipoproteins and the Prevalence of Coronary Artery Disease in Whites
M Orth, W Weng, H Funke, A Steinmetz, G Assmann, M Nauck, J Dierkes, ...
Arteriosclerosis, thrombosis, and vascular biology 19 (5), 1306-1315, 1999
601999
Multi-center analytical evaluation of a novel automated tacrolimus immunoassay
M Shipkova, M Vogeser, PA Ramos, AG Verstraete, M Orth, C Schneider, ...
Clinical biochemistry 47 (12), 1069-1077, 2014
572014
Multicenter analytical evaluation of the automated electrochemiluminescence immunoassay for cyclosporine
M Vogeser, M Shipkova, R Rigo-Bonnin, P Wallemacq, M Orth, ...
Therapeutic Drug Monitoring 36 (5), 640-650, 2014
382014
Clearance of postprandial lipoproteins in normolipemics: role of the apolipoprotein E phenotype
M Orth, S Wahl, M Hanisch, I Friedrich, H Wieland, C Luley
Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism 1303 (1), 22-30, 1996
371996
Autoverification of test results in the core clinical laboratory
EW Randell, S Yenice, AAK Wamono, M Orth
Clinical biochemistry 73, 11-25, 2019
362019
Comparability and imprecision of 8 frequently used commercially available immunoassays for therapeutic drug monitoring
M Shipkova, DT Petrova, AE Rosler, M Orth, J Engelmayer, E Wieland, ...
Therapeutic drug monitoring 36 (4), 433-441, 2014
332014
Effects of VLDL, chylomicrons, and chylomicron remnants on platelet aggregability
M Orth, C Luley, H Wieland
Thrombosis research 79 (3), 297-305, 1995
301995
The diagnostic value of serum homocysteine concentration as a risk factor for coronary artery disease
J Dierkes, E Bissé, M Nauck, M Orth, H Mayer, C Luley, H Wieland
Walter de Gruyter 36 (7), 453-457, 1998
261998
Implementation of the new EU IVD regulation–urgent initiatives are needed to avert impending crisis
C Cobbaert, ED Capoluongo, FJLA Vanstapel, PMM Bossuyt, HP Bhattoa, ...
Clinical Chemistry and Laboratory Medicine (CCLM) 60 (1), 33-43, 2022
252022
Human serum gangliosides in hypercholesterolemia, before and after extracorporeal elimination of LDL
HJ Senn, M Orth, E Fitzke, W Köster, H Wieland, W Gerok
Atherosclerosis 94 (2-3), 109-117, 1992
221992
ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro …
FJLA Vanstapel, M Orth, T Streichert, ED Capoluongo, WP Oosterhuis, ...
Clinical Chemistry and Laboratory Medicine (CCLM) 61 (4), 608-626, 2023
202023
Commutability assessment of candidate reference materials for pancreatic α-amylase
L Deprez, B Toussaint, I Zegers, H Schimmel, D Grote-Koska, R Klauke, ...
Clinical chemistry 64 (8), 1193-1202, 2018
172018
The system can't perform the operation now. Try again later.
Articles 1–20